Christopher Kirk's Insider Trades & SAST Disclosures
Christopher Kirk's most recent trade in Kezar Life Sciences Inc was a trade of 120,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 9, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Christopher Kirk.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kezar Life Sciences Inc | Christopher Kirk | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2025 | 120,000 | 120,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Christopher Kirk | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 260,000 | 260,000 | - | - | Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Christopher Kirk | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 260,000 | 0 | - | - | Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Christopher Kirk | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 190,000 | 190,000 | - | - | Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Christopher Kirk | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 190,000 | 0 | - | - | Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Christopher Kirk | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 170,000 | 0 | - | - | Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Christopher Kirk | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 170,000 | 170,000 | - | - | Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Christopher Kirk | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Christopher Kirk | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 125,000 | 0 | - | - | Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Christopher Kirk | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 87,500 | 0 | - | - | Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Christopher Kirk | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 87,500 | 87,500 | - | - | Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Christopher Kirk | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 20 Jul 2023 | 48,950 | 431,348 (1%) | 0% | 0.9 | 44,055 | Common Stock |
| Kezar Life Sciences Inc | Christopher Kirk | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jul 2023 | 48,950 | 74,411 | - | - | Employee Stock Option (right to buy) | |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 23,102 | 173,708 (0%) | 0% | 0 | Class A Common Stock | |
| Kezar Life Sciences Inc | Christopher Kirk | Director, President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2023 | 190,000 | 190,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Christopher Kirk | Director, President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2022 | 33,060 | 123,361 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Christopher Kirk | Director, President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 23 Jun 2022 | 33,060 | 381,484 (0%) | 0% | 0.9 | 29,754 | Common Stock |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 2,918 | 150,606 (0%) | 0% | 0 | Class A Common Stock | |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 77.70 per share. | 10 May 2022 | 7,916 | 150,888 (0%) | 0% | 77.7 | 615,093 | Class A Common Stock |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 78.98 per share. | 10 May 2022 | 5,929 | 158,804 (0%) | 0% | 79.0 | 468,268 | Class A Common Stock |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 10 May 2022 | 3,200 | 147,688 (0%) | 0% | 0 | Class A Common Stock | |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 79.39 per share. | 10 May 2022 | 1,315 | 164,733 (0%) | 0% | 79.4 | 104,399 | Class A Common Stock |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 95.39 per share. | 03 Mar 2022 | 2,441 | 166,048 (0%) | 0% | 95.4 | 232,847 | Class A Common Stock |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.85 per share. | 28 Feb 2022 | 1,965 | 168,489 (0%) | 0% | 96.8 | 190,310 | Class A Common Stock |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 13,434 | 170,454 (0%) | 0% | 0 | Class A Common Stock | |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 26,502 | 157,020 (0%) | 0% | 0 | Class A Common Stock | |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.65 per share. | 16 Feb 2022 | 980 | 130,518 (0%) | 0% | 101.7 | 99,617 | Class A Common Stock |
| Kezar Life Sciences Inc | Christopher Kirk | Director, President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 170,000 | 170,000 | - | - | Employee Stock Option (right to buy) | |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 97.19 per share. | 04 Aug 2021 | 9,900 | 131,498 (0%) | 0% | 97.2 | 962,182 | Class A Common Stock |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 96.80 per share. | 04 Aug 2021 | 8,100 | 141,398 (0%) | 0% | 96.8 | 784,066 | Class A Common Stock |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 11,551 | 152,085 (0%) | 0% | 0 | Class A Common Stock | |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.91 per share. | 03 Mar 2021 | 2,587 | 149,498 (0%) | 0% | 77.9 | 201,553 | Class A Common Stock |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 3,762 | 140,534 (0%) | 0% | 0 | Class A Common Stock | |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.77 per share. | 28 Feb 2021 | 1,411 | 136,772 (0%) | 0% | 75.8 | 106,911 | Class A Common Stock |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.56 per share. | 16 Feb 2021 | 5,661 | 138,183 (0%) | 0% | 70.6 | 399,440 | Class A Common Stock |
| Kezar Life Sciences Inc | Christopher Kirk | Director, President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2021 | 260,000 | 260,000 | - | - | Employee Stock Option (right to buy) | |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.20 per share. | 11 Aug 2020 | 1,483 | 143,844 (0%) | 0% | 47.2 | 69,998 | Class A Common Stock |
| CBRE Group Inc - Ordinary ... | J. Christopher Kirk | Global Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 53.51 per share. | 09 Jun 2020 | 19,500 | 145,327 (0%) | 0% | 53.5 | 1,043,381 | Class A Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges